Biogen Financials
BIIB Stock | USD 146.23 1.82 1.26% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Debt Equity Ratio | 0.47 | 0.45 |
|
| |||||
Current Ratio | 2.18 | 2.3 |
|
|
Investors should never underestimate Biogen's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Biogen's cash flow, debt, and profitability to make informed and accurate decisions about investing in Biogen Inc.
Net Income |
|
Biogen | Select Account or Indicator |
Understanding current and past Biogen Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Biogen's financial statements are interrelated, with each one affecting the others. For example, an increase in Biogen's assets may result in an increase in income on the income statement.
Biogen Inc Earnings Geography
Please note, the presentation of Biogen's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Biogen's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Biogen's management manipulating its earnings.
Biogen Stock Summary
Biogen competes with Bristol Myers, AbbVie, Merck, Gilead Sciences, and Johnson Johnson. Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts. Biogen operates under Drug ManufacturersGeneral classification in the United States and is traded on NASDAQ Exchange. It employs 9610 people.Foreign Associate | Mexico |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US09062X1037 |
CUSIP | 09062X103 449370105 |
Location | Massachusetts; U.S.A |
Business Address | 225 Binney Street, |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.biogen.com |
Phone | 617 679 2000 |
Currency | USD - US Dollar |
Biogen Key Financial Ratios
Return On Equity | 0.1 | ||||
Profit Margin | 0.17 % | ||||
Operating Margin | 0.21 % | ||||
Price To Sales | 2.19 X | ||||
Revenue | 9.84 B |
Biogen Key Balance Sheet Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Total Assets | 24.6B | 23.9B | 24.6B | 26.8B | 30.9B | 32.4B | |
Other Current Liab | 3.1B | 2.4B | 2.4B | 2.5B | 2.9B | 3.1B | |
Net Debt | 6.5B | 5.3B | 3.2B | 6.3B | 7.2B | 7.6B | |
Retained Earnings | 14.0B | 13.9B | 16.5B | 17.6B | 20.3B | 21.3B | |
Cash | 1.3B | 2.3B | 3.4B | 1.0B | 1.2B | 723.1M | |
Net Receivables | 2.3B | 2.0B | 2.1B | 2.1B | 2.4B | 2.5B | |
Other Current Assets | 881.1M | 740.8M | 1.4B | 1.2B | 1.4B | 1.4B | |
Total Liab | 13.9B | 12.9B | 11.2B | 12.0B | 13.9B | 14.5B | |
Total Current Assets | 6.9B | 7.9B | 9.8B | 6.9B | 7.9B | 8.3B | |
Intangible Assets | 3.1B | 2.2B | 1.9B | 8.4B | 9.6B | 10.1B | |
Accounts Payable | 454.9M | 589.2M | 491.5M | 403.3M | 463.8M | 487.0M | |
Short Term Debt | 83.2M | 1.1B | 97.2M | 240.3M | 276.3M | 261.4M | |
Inventory | 1.1B | 1.4B | 1.3B | 2.5B | 2.9B | 3.1B | |
Other Liab | 4.2B | 2.4B | 2.0B | 1.3B | 1.5B | 969.6M | |
Other Assets | 3.2B | 4.2B | 3.4B | 1.7B | 1.9B | 2.0B | |
Long Term Debt | 7.4B | 6.3B | 6.3B | 6.8B | 7.8B | 8.2B | |
Good Will | 5.8B | 5.8B | 5.7B | 6.2B | 7.2B | 7.5B | |
Net Tangible Assets | 4.1B | 1.9B | 2.9B | 5.8B | 6.7B | 4.1B |
Biogen Key Income Statement Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Interest Expense | 222.5M | 253.6M | 246.6M | 246.9M | 283.9M | 298.1M | |
Total Revenue | 13.4B | 11.0B | 10.2B | 9.8B | 11.3B | 11.9B | |
Gross Profit | 11.6B | 8.9B | 7.9B | 7.3B | 8.4B | 8.8B | |
Operating Income | 4.6B | 2.8B | 2.3B | 2.1B | 2.4B | 1.6B | |
Ebit | 5.3B | 2.0B | 3.8B | 1.9B | 2.2B | 1.7B | |
Ebitda | 5.7B | 2.5B | 4.4B | 2.4B | 2.7B | 1.9B | |
Cost Of Revenue | 1.8B | 2.1B | 2.3B | 2.5B | 2.9B | 3.1B | |
Income Before Tax | 5.0B | 1.7B | 3.6B | 1.3B | 1.5B | 1.6B | |
Net Income | 4.0B | 1.6B | 3.0B | 1.2B | 1.3B | 1.2B | |
Income Tax Expense | 992.3M | 52.5M | 632.8M | 135.3M | 155.6M | 147.8M | |
Research Development | 4.0B | 2.5B | 2.2B | 2.7B | 3.1B | 3.3B | |
Minority Interest | 59.9M | 171.5M | 85.3M | (400K) | (460K) | (437K) | |
Non Recurring | 1.5M | 75M | 18M | 131.1M | 118.0M | 99.1M | |
Tax Provision | 992.3M | 52.5M | 632.8M | 135.3M | 121.8M | 115.7M | |
Interest Income | 42M | 11M | 89.3M | 276.5M | 318.0M | 333.9M | |
Net Interest Income | (180.5M) | (242.6M) | (157.3M) | 29.6M | 34.0M | 35.7M |
Biogen Key Cash Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Change In Cash | (1.6B) | 930.2M | 1.2B | (2.4B) | (2.1B) | (2.0B) | |
Free Cash Flow | 3.7B | 3.3B | 1.1B | 1.2B | 1.4B | 1.3B | |
Depreciation | 457.2M | 487.7M | 518.4M | 494.8M | 569.0M | 348.0M | |
Other Non Cash Items | (448M) | 1.8B | (1.3B) | 581.2M | 668.4M | 701.8M | |
Capital Expenditures | 551.8M | 294.9M | 243.2M | 311.4M | 358.1M | 429.3M | |
Net Income | 4.1B | 1.7B | 3.0B | 1.2B | 1.3B | 1.3B | |
End Period Cash Flow | 1.3B | 2.3B | 3.4B | 1.0B | 1.2B | 800.3M | |
Change To Inventory | (316.3M) | (462.4M) | (320.2M) | (130.9M) | (117.8M) | (123.7M) | |
Investments | (29.9M) | (309.8M) | 1.6B | (4.1B) | (3.7B) | (3.5B) | |
Change Receivables | 68.8M | 2.8M | 324.8M | (203.4M) | (233.9M) | (245.6M) | |
Change To Netincome | 254.9M | 673.6M | 743.3M | (1.5B) | (1.3B) | (1.3B) |
Biogen Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Biogen's current stock value. Our valuation model uses many indicators to compare Biogen value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Biogen competition to find correlations between indicators driving Biogen's intrinsic value. More Info.Biogen Inc is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers reporting about 0.48 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Biogen Inc is roughly 2.10 . At present, Biogen's Return On Equity is projected to increase slightly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Biogen's earnings, one of the primary drivers of an investment's value.Biogen's Earnings Breakdown by Geography
Biogen Inc Systematic Risk
Biogen's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Biogen volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty with a total number of output elements of thirty-one. The Beta measures systematic risk based on how returns on Biogen Inc correlated with the market. If Beta is less than 0 Biogen generally moves in the opposite direction as compared to the market. If Biogen Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Biogen Inc is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Biogen is generally in the same direction as the market. If Beta > 1 Biogen moves generally in the same direction as, but more than the movement of the benchmark.
Biogen Thematic Clasifications
Biogen Inc is part of Hedge Favorites investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Investment assets that are popular or favored by hedge funds. Hedge Funds pool capital from accredited individuals or institutional investors and invest in a variety of assets, often with complex portfolio-construction and risk-management techniques.
This theme covers Investment assets that are popular or favored by hedge funds. Hedge Funds pool capital from accredited individuals or institutional investors and invest in a variety of assets, often with complex portfolio-construction and risk-management techniques. . Get More Thematic Ideas
Hedge Favorites | View |
Today, most investors in Biogen Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Biogen's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Biogen growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Biogen January 30, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Biogen help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Biogen Inc. We use our internally-developed statistical techniques to arrive at the intrinsic value of Biogen Inc based on widely used predictive technical indicators. In general, we focus on analyzing Biogen Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Biogen's daily price indicators and compare them against related drivers.
Information Ratio | (0.30) | |||
Maximum Drawdown | 6.98 | |||
Value At Risk | (2.97) | |||
Potential Upside | 1.83 |
Complementary Tools for Biogen Stock analysis
When running Biogen's price analysis, check to measure Biogen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biogen is operating at the current time. Most of Biogen's value examination focuses on studying past and present price action to predict the probability of Biogen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biogen's price. Additionally, you may evaluate how the addition of Biogen to your portfolios can decrease your overall portfolio volatility.
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |